Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 219,937,492 papers from all fields of science
Search
Sign In
Create Free Account
Subrenal Capsule Assay
Known as:
Subrenal Capsule Assays
, Assay, Subrenal Capsule
, Assays, Subrenal Capsule
Expand
In vivo method of screening investigative anticancer drugs and biologic response modifiers for individual cancer patients. Fresh tumor tissue is…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Xenograft Model Antitumor Assays
standards characteristics
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
J. Mäenpää
,
E. Heinonen
,
+16 authors
M. Väyrynen
Gynecologic Oncology
1995
Corpus ID: 21912248
In order to find out whether the response rate and survival in epithelial ovarian cancer can be improved by aid of sensitivity…
Expand
Highly Cited
1987
Highly Cited
1987
Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay.
H. Fingert
,
Z. Chen
,
N. Mizrahi
,
W. Gajewski
,
M. Bamberg
,
R. Kradin
Cancer Research
1987
Corpus ID: 20329088
Rapid in vivo growth of cultured human cancer or leukemia cells was achieved by implantation into the subrenal capsule of mice. A…
Expand
1987
1987
[Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Y. Wang
,
K. Inoue
,
H. Shibata
,
Y. Itoh
,
S. Chen
,
M. Ogawa
Gan to kagaku ryoho. Cancer & chemotherapy
1987
Corpus ID: 20845074
CPT-11 is a new derivative of camptothecin, a plant alkaloid developed in Japan. We investigated the antitumor activity of CPT-11…
Expand
Review
1985
Review
1985
The subrenal capsule assay (SRCA) and its predictive value in oncology.
Bogden Ae
1985
Corpus ID: 58342157
: This report has been prepared as a mini-review of the studies and data, accumulated by a number of investigators since 1978…
Expand
1985
1985
Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents.
S. Aamdal
,
O. Fodstad
,
A. Pihl
Anticancer Research
1985
Corpus ID: 24512005
Methodological aspects of testing chemosensitivity by the 6-day subrenal capsule (SRC) assay in immunocompetent mice were…
Expand
1984
1984
Comparison of the human tumor cloning and subrenal capsule assays.
A. Bogdén
,
D. V. Von Hoff
Cancer Research
1984
Corpus ID: 10010154
Fresh surgical explants of solid tumors obtained from 84 patients were tested against the same chemotherapeutic agents in both…
Expand
1984
1984
The subrenal capsule assay in mice. Prediction of rat tumor sensitivity to chemotherapy
J. Mäenpää
,
M. Grönroos
,
Milla Leppänen
,
L. Kangas
Cancer
1984
Corpus ID: 29683713
The predictive value of the subrenal capsule (SRC) assay for cancer chemotherapy was tested in five rat tumors. Tumor‐bearing…
Expand
Highly Cited
1984
Highly Cited
1984
Predictive testing with the subrenal capsule assay.
A. Bogdén
,
W. Griffin
,
S. Reich
,
M. Costanza
,
W. Cobb
Cancer Treatment Reviews
1984
Corpus ID: 20094986
Highly Cited
1983
Highly Cited
1983
Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy
T. Griffin
,
A. Bogdén
,
+6 authors
M. Costanza
Cancer
1983
Corpus ID: 40787000
Retrospective and prospective clinical trials were performed to determine the usefulness of the 6‐day subrenal capsule (SRC…
Expand
1983
1983
Single agent chemotherapy for head and neck cancers. The murine subrenal capsule assay.
K. Mccormick
,
W. Panje
,
S. Seltzer
,
R. H. Merrick
A M A Archives of Otolaryngology
1983
Corpus ID: 36768292
The murine subrenal capsule assay was used to determine chemotherapeutic sensitivities of metastatic, primary, or recurrent head…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE